The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an NAE inhibitor or a pharmaceutically acceptable salt thereof, such as ((lS,2S,4R)-4-(4-((lS)-2,3-dihydro-lH-inden-l-ylamino)-7H-pyrrolo[2,3 d]pyrimidin 7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or {(lS,2S,4R)-4-[(6-{[(lR,2S)-5-chloro-2 methoxy-2,3-dmydro-lH-mden-l-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl} -methyl sulfamate (1-216), and a hypomethylating agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine. Also disclosed are medicaments for use in the treatment of cancer.
